Clinical Trial Update: Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 biodistribution study of the 186Re-labeled humanized monoclonal antibody BIWA-4 in patients with non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIWA-4 (186Re-labeled humanized monoclonal antibody) (BIWA-4)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED